Obstetric medicine · 2024
Influence of aspirin on obstetric outcomes in women with pre-gestational diabetes mellitus: a South-Western Sydney cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jeyaruban Andrew, Shanmugalingam Renuka, Wu Pamela, Cao Rena, Wong Vincent W, Wong Tang, Flack Jeff, Makris Angela
Аннотация
AIM: To investigate the effect of aspirin on obstetric outcomes in women with pre-gestational diabetes mellitus (PGDM).
METHOD: Retrospective audit of pregnant women with PGDM from two centres in South-Western Sydney was conducted. Women were categorised into the aspirin group (prescribed aspirin before 16 weeks, gestation) and non-aspirin group (not prescribed aspirin or prescribed aspirin at or after 16 weeks, gestation). The outcomes examined were pre-eclampsia, pre-term delivery and birthweight percentile.
RESULTS: Of 494 women, 52 (10.5%) were in the aspirin group. Pre-eclampsia developed in 57 (12.0%) women. There was no association between aspirin use and pre-eclampsia (8 (15.4%) vs 49 (11.1%), P = 0.2). Aspirin use was not associated with difference in birthweight percentile and rate of pre-term deliveries when adjusted for maternal age, gravidity and other comorbidities.
CONCLUSION: There was no difference in the rates of pre-eclampsia, pre-term delivery, or birthweight percentile between women with PGDM in aspirin group compared to women in non-aspirin group.
METHOD: Retrospective audit of pregnant women with PGDM from two centres in South-Western Sydney was conducted. Women were categorised into the aspirin group (prescribed aspirin before 16 weeks, gestation) and non-aspirin group (not prescribed aspirin or prescribed aspirin at or after 16 weeks, gestation). The outcomes examined were pre-eclampsia, pre-term delivery and birthweight percentile.
RESULTS: Of 494 women, 52 (10.5%) were in the aspirin group. Pre-eclampsia developed in 57 (12.0%) women. There was no association between aspirin use and pre-eclampsia (8 (15.4%) vs 49 (11.1%), P = 0.2). Aspirin use was not associated with difference in birthweight percentile and rate of pre-term deliveries when adjusted for maternal age, gravidity and other comorbidities.
CONCLUSION: There was no difference in the rates of pre-eclampsia, pre-term delivery, or birthweight percentile between women with PGDM in aspirin group compared to women in non-aspirin group.